PMCCPMCCPMCC

Conseils de recherche
Les critères de recherche 

Avancée

 
Logo of autoimmdisJournal's HomeManuscript SubmissionAims and ScopeAuthor GuidelinesEditorial BoardHome
 
Autoimmune Dis. 2012; 2012: 728605.
Published online Oct 4, 2012. doi:  10.1155/2012/728605
PMCID: PMC3471389
Role of Hsp90 in Systemic Lupus Erythematosus and Its Clinical Relevance
Hem D. Shukla 1 * and Paula M. Pitha 1 , 2
1Department of Biology, Johns Hopkins University, Baltimore, MD 21218, USA
2Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
*Hem D. Shukla: hshukla2/at/jhu.edu
Academic Editor: Kamal D. Moudgil
Received July 14, 2012; Accepted September 6, 2012.
Abstract
Heat shock proteins (HSP) are a family of ubiquitous and phylogenically highly conserved proteins which play an essential role as molecular chaperones in protein folding and transport. Heat Shock Protein 90 (Hsp90) is not mandatory for the biogenesis of most proteins, rather it participate in structural maturation and conformational regulation of a number of signaling molecules and transcription factors. Hsp90 has been shown to play an important role in antigen presentation, activation of lymphocytes, macrophages, maturation of dendritic cells, and in the enhanceosome mediated induction of inflammation. Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease with complex immunological and clinical manifestations. Dysregulated expression of Type I interferon α, activation of B cells and production of autoantibodies are hallmarks of SLE. The enhanced levels of Hsp90 were detected in the serum of SLE patients. The elevated level of Hsp90 in SLE has also been correlated with increased levels of IL-6 and presence of autoantibodies to Hsp90. This suggests that Hsp90 may contribute to the inflammation and disease progression and that targeting of Hsp 90 expression may be a potential treatment of SLE. The pharmacologic inhibition of Hsp90 was successfully applied in mouse models of autoimmune encephalomyelitis and SLE—like autoimmune diseases. Thus targeting Hsp90 may be an effective treatment for SLE, especially if combined with other targeted therapeutic approaches.
Articles from Autoimmune Diseases are provided here courtesy of
Hindawi Publishing Corporation